CD19 and acute lymphoblastic leukemia: Moreover, a median EFS of 7.6 months and a median OS of 20.0 months have been reported by Hay et al.31 in adult R/R B-ALL patients achieving MRD-negative CR after CD19-CAR-T cell therapy.